

Remarks

Applicant thanks the Office for correcting the sequence listing and for restarting the period for responding to the Office Action.

Unexamined subject matter

Claims 1, 2, and 16-23 have been examined with respect to propylthiouracil as the elected species thyroid hormone-lowering agent. If the these claims are found allowable with respect to the elected species of propylthiouracil, Applicant respectfully requests that the patentability of claims 1, 16-23, and new claims 24 and 25 be considered with respect to the other species of thyroid hormone-lowering agent recited in claims 3-5. M.P.E.P. § 809.02(e).

The Amendments

Claim 1 is amended to recite that the amount of the administered thyroid hormone lowering agent “effective to decrease a level of a thyroid hormone in the mammal to a low normal level or to a below normal level.” See Example 5, which teaches low normal and below normal levels of thyroid hormones in healer vs. non-healer mice.

New claim 24 is supported at page 3, lines 26-27: “Wounds whose healing can be increased according to the invention include, but are not limited to, ischemic infarcts . . .” New claim 25 is supported *inter alia* by Examples 2, 3, 5, and 8, which teach detection of increased healing.

Neither the amendments nor the new claims add new matter. No new search is required.

The Rejection of Claims 1, 2, 16-19, 21, and 23 Under 35 U.S.C. § 102(b)

Claims 1, 2, 16-19, 21, and 23 stand rejected under 35 U.S.C. § 102(b) as anticipated by Corte *et al.*, *Gass. Med. Ital. Arch. Aci. Med.* 152, 149-53, 1993 (“Corte”). Applicant respectfully traverses the rejection.

A printed publication that antedates an invention under 35 U.S.C. § 102 must disclose each element of the invention. *Kalman v. Kimberly-Clark Corp.*, 218 U.S.P.Q. 781, 789 (Fed. Cir. 1983), *cert. denied*, 465 U.S. 1026 (1984). Corte does not meet this standard.

Corte is cited as teaching increased healing of an ischemic heart in a human patient by administering propylthiouracil after ischemic injury occurred. Office Action at page 3. Corte, however, does not teach all the elements of amended independent claim 1. Independent claim 1 has been amended to recite that the amount of the administered thyroid hormone lowering agent “effective to decrease a level of a thyroid hormone in the mammal to a low normal level or to a below normal level.” Corte does not teach this element of claim 1.

The human patient described in Corte was “a patient affected with hyperthyroidism, who during a thyrotoxic crisis developed acute myocardial ischemia” Page 3, third paragraph of the translation. Upon administration to the hospital her T3 level was 400 ng/dL and her T4 level was 20 μ g/dL. Page 6, first paragraph. These TH levels are above the normal range for humans, which is 100-200 ng/dL for T3 and 5-12 μ g/dL for T4. See Attachment 1. The patient was treated with propylthiouracil and propanolol.

After propylthiouracil treatment, this patient’s thyroid hormone levels were not decreased to a low normal level or to a below normal level, as recited in amended claim 1. After three

months of propylthiouracil therapy, the patient's T3 level was 200 ng/dL and her T4 level was 12 µg/dL. Page 7, third full paragraph. These levels are each at the high end of the normal range. The specification teaches that low normal or below normal TH levels are associated with wound healing. See Example 4. It is, therefore, unlikely that the propylthiouracil treatment increased healing of the patient's ischemic damage. In fact, Corte teaches that “[t]he rapidity of the regression of electrocardiographic signs of ischemia and the clinical improvement are to be attributed to the action of the Propanolol, given that Propylthiouracil needs a greater lapse of time to perform its effects.”. Page 9, second full paragraph.

Corte does not teach that administration of propylthiouracil to the patient was “effective to decrease a level of a thyroid hormone in the mammal to a low normal level or to a below normal level,” as recited in amended claim 1. Thus, Corte does not teach each element of amended claim 1 and therefore does not anticipate claims 1, 2, 16-19, 21, or 23. Because new claims 24 and 25 depend from claim 1, Corte also does not anticipate these claims.

Applicant respectfully requests withdrawal of the rejection.

The Rejection of Claims 1, 2, 17-20, 22, and 23 Under 35 U.S.C. § 102(b)

Claims 1, 2, 17-20, 22, and 23 stand rejected under 35 U.S.C. § 102(b) as anticipated by Alpert *et al.*, *Eur. Heart J.* 5, 3-11, 1984 (“Alpert”). Applicant respectfully traverses the rejection.

Alpert is cited as teaching administration of propylthiouracil to a WKY rat prior to and concomitant with wounding the heart by removing myofibrils for *in vitro* experiments. Office

Action at page 4. The Office Action acknowledges that Alpert does not teach that levels of T3 or T4 are lowered or that reepithelialization occurs, but asserts that these results of propylthiouracil administration are inherent in Alpert's disclosure. Office Action at page 4.

To establish inherency, extrinsic evidence "must make clear that the missing descriptive matter is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill." *Continental Can Co. v. Monsanto Co.*, 948 F.2d 1264, 1268, 20 U.S.P.Q.2d 1746, 1759 (Fed. Cir. 1991) (emphasis added). Alpert does not meet this standard. Alpert discloses *in vitro* experiments carried out on myofibrils removed from either control rats or rats treated with propylthiouracil. Page 4, col. 2. Rather than healing from the removal of myofibrils, it is evident that neither group of rats survived. Table 1 of Alpert discloses the body and heart weights of the two groups of rats. See page 6, col. 2. To weigh a heart, it must be removed from the body; it is self-evident that a rat would not survive removal of its heart. Thus, no healing of a heart wound in a propylthiouracil-treated mammal inherently occurred at all in Alpert's rats, much less increased healing.

Alpert does not explicitly or inherently disclose the invention of claims 1, 2, 17-20, 22, or 23, or of new dependent claim 24. New claim 25 recites a step of detecting increased healing of a heart wound. Alpert neither explicitly nor inherently discloses this step.

Applicant respectfully requests withdrawal of the rejection.

Respectfully submitted,
BANNER & WITCOFF, Ltd.


Date: April 7, 2003

By: Lisa M. Hemmendinger
Lisa M. Hemmendinger
Registration No. 42,653

1001 G Street, N.W., Eleventh Floor
Washington, D.C. 20001-4597
(202) 508-9100

CECIL
TEXTBOOK
OF
MEDICINE

20TH EDITION
VOLUME 2



Edited by

J. CLAUDE BENNETT, M.D.

President, University of Alabama at Birmingham
Birmingham, Alabama;
Formerly Spencer Professor of Medicine
and Chairman, Department of Medicine
University of Alabama School of Medicine
Birmingham, Alabama

FRED PLUM, M.D.

~~Anne~~ Parrish Titzell Professor of Neurology and Neuroscience
Chairman, Department of Neurology and Neuroscience
Cornell University Medical College;
Neurologist-in-Chief
The New York Hospital-Cornell Medical Center
New York, New York

W.B. SAUNDERS COMPANY

A Division of Harcourt Brace & Company

PHILADELPHIA • LONDON • TORONTO • MONTREAL • SYDNEY • TOKYO

W. B. SAUNDERS COMPANY
A Division of Harcourt Brace & Company

The Curtis Center
Independence Square West
Philadelphia, PA 19106

Library of Congress Cataloging-in-Publication Data

Cecil textbook of medicine / edited by J. Claude Bennett, Fred Plum.—20th ed.

p. cm.

Includes bibliographical references and index.

ISBN 0-7216-3561-X (single v.).—ISBN 0-7216-3574-1 (v. 1).—ISBN 0-7216-3575-X (v. 2).—
ISBN 0-7216-3573-3 (set)

1. Internal medicine. I. Cecil, Russell L. (Russell La Fayette), 1881–1965. II. Bennett, J. Claude.
III. Plum, Fred. IV. Title: Textbook of medicine.
[DNLM: 1. Medicine. WB 100 C3888 1996]

RC46.C423 1996
616—dc20

DNLM/DLC

94-43773

CECIL TEXTBOOK OF MEDICINE

ISBN 0-7216-3574-1 Volume 1
ISBN 0-7216-3575-X Volume 2
ISBN 0-7216-3573-3 Set (Vols 1 & 2)
ISBN 0-7216-3561-X Single volume

Copyright © 1996, 1991, 1988, 1985, 1982, 1979, 1975, 1971, 1963, 1959, 1955 by W. B. Saunders Company.

Copyright 1951, 1947, 1943, 1940, 1937, 1933, 1930, 1927 by W.B. Saunders Company.

Copyright renewed 1991 by Paul Beeson.

Copyright renewed 1979 by Russell L. Cecil and Robert F. Loeb.

Copyright renewed 1987, 1975, 1971, 1965, 1961, 1958, 1955 by W. B. Saunders Company.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Printed in the United States of America.

Last digit is the print number: 9 8 7 6 5 4 3 2

CLINICAL CHEMISTRY, TOXICOLOGY, SEROLOGY *Continued*

Test	Specimen	Reference Interval (Conventional Units)	Reference Interval (International Units)
Sodium	Serum or plasma (heparin) Urine, 24-h	136-146 mEq/L 40-120 mmol/d	136-146 mmol/L 40-120 mmol/d
Specific gravity	Urine, random Urine, 24-h	1.001-1.031 1.015-1.025	1.002-1.030 1.015-1.025
Testosterone, free	Serum	M: 52-220 pg/mL F: 16-63 pg/mL	180.4-971.6 pmol/fraction of total L 5.6-21.9 pmol/L 0.015-0.032 0.008-0.014
Testosterone, total	Serum	M: 106-166 F: 24-75	10.4-34.7 nmol/L 0.69-2.6 nmol/L
	Urine	26-50 M: 56-155 μ g/d F: 2-12 μ g/d M: 30-60 μ g/d F: 2-5 μ g/d	173-470 nmol/d 7-42 nmol/d 139-210 nmol/d 7-28 nmol/d
Thiamine (see Vitamin B ₁)	Serum	< 42 ng/mL	3-42 μ g/L
Thyroglobulin (Tg)	Serum		< 1:10
Thyroglobulin antibodies	Serum		Not detectable (hemagglutination) or < 1:10 (IFA)
Thyroid microsomal antibodies	Serum		
Thyrotropin (hTSH)	Serum or plasma	2-10 μ U/mL	2-10 mU/L
Thyrotropin-releasing hormone	Plasma	5-60 pg/mL	5-60 ng/L
Thyroxine, free (FT ₄)	Serum	0.8-2.4 ng/dL	10-31 pmol/L
Thyroxine (T ₄), total	Serum	5-12 μ g/dL > 60 y: M: 5.0-10.0 μ g/dL F: 5.5-10.5 μ g/dL	65-155 nmol/L 65-129 nmol/L 71-135 nmol/L
Thyroxine-binding globulin (TBG)	Serum	15.0-34.0 μ g/mL	15.0-34.0 mg/L
Thyroxine index, free (see Free thyroxine index)			
Transcortin	Serum	T ₄ (μ g/dL)/TBG (μ g/mL) M: 18.8-25.2 mg/L F: 14.9-22.9 mg/L	T ₄ (nmol/L)/TBG (mg/L) 323-433 nmol/L 256-393 nmol/L
Transferrin	Serum	200-400 mg/dL > 60 y: 180-380 mg/dL	2.0-4.0 g/L 1.80-3.80 g/L
Transthyretin (prealbumin)	Serum	10-40 mg/dL	100-400 mg/L
Triglycerides (TG)	Serum, after \geq 12-hr fast	Recommended: M: 40-160 mg/dL F: 35-135 mg/dL	0.45-1.81 mmol/L 0.40-1.52 mmol/L
Tri-iodothyronine, free	Serum	260-480 pg/dL	4.0-7.4 pmol/L
Tri-iodothyronine, total (T ₃)	Serum	100-200 ng/dL	1.54-3.08 mmol/L
Tri-iodothyronine resin uptake test (T ₃ RU)	Serum	24-34%	24-34 AU (arbitrary units)
Urea nitrogen	Serum or plasma	7-18 mg/dL	2.5-6.4 mmol/L
Urea nitrogen/creatinine ratio	Urine	12-20 g/d	0.43-0.71 mol/d 12/1-20/1
Uric acid (uricase)	Serum	M: 3.5-7.2 mg/dL F: 2.6-6.0 mg/dL	0.21-0.42 mmol/L 0.15-0.35 mmol/L
Urine, 24-h		250-750 mg/d	1.48-4.43 mmol/d
Urinary sediment (see Sediment)			
Urobilinogen	Urine, 2-h Urine, 24-h Feces	0.1-0.8 EU 0.5-4.0 EU 75-275 EU/100 g 75-400 EU/d 40-280 mg/d < 50 μ g/d 10-40 μ g/d	0.1-0.8 U 0.5-4.0 U 750-2750 U/kg 75-400 U/d 67-473 μ mol/d < 60 nmol/d 12-48 nmol/d Negative
Uroporphyrin	Urine, 24-h Feces, 24-h specimen	2-7 mg/d	10.1-35.4 μ mol/d 1.10-1.22 centipoise
Vanillylmandelic acid (VMA)	Erythrocytes (heparin or EDTA)	30-80 μ g/dL	1.05-2.8 μ mol/L
Viscosity	Serum	0-2 μ g/dL	0-75 nmol/L
Vitamin A	Serum	4-24 μ g/dL	106-638 nmol/L
Vitamin B ₁ (Thiamine)	Serum	5-30 ng/mL	20-121 nmol/L
Vitamin B ₂ (Riboflavin)	Serum	100-700 pg/mL	74-516 pmol/L
Vitamin B ₆	Plasma (EDTA)	0.5-1.5 mg/dL	28-85 μ mol/L
Vitamin B ₁₂	Serum	25-45 pg/mL	60-108 pmol/L
Vitamin C	Plasma (oxalate, heparin, or EDTA)	Summer: 15-80 ng/mL Winter: 14-42 ng/mL	37.4-200 nmol/L 34.9-105 nmol/L
Vitamin D ₂ , 1,25-dihydroxy	Serum		
Vitamin D ₃ , 25-hydroxy	Plasma (heparin)		
Vitamin E	Serum	5.0-18.0 μ g/mL	12-42 μ mol/L
Zinc	Serum	70-150 μ g/dL	10.7-22.9 μ mol/L